These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28043676)

  • 1. Cardiovascular safety of incretin-based therapy for type 2 diabetes: A meta-analysis of randomized trials.
    Mahmoud AN; Saad M; Mansoor H; Elgendy AY; Barakat AF; Abuzaid A; Mentias A; Elgendy IY
    Int J Cardiol; 2017 Mar; 230():324-326. PubMed ID: 28043676
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.
    Fisher M; Petrie MC; Ambery PD; Donaldson J; Ye J; McMurray JJ
    Lancet Diabetes Endocrinol; 2015 Sep; 3(9):697-703. PubMed ID: 26276240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin-based therapy for type 2 diabetes: A real class effect?
    Savarese G; Lund LH; Rosano GMC
    Int J Cardiol; 2017 Jan; 227():141-142. PubMed ID: 27866064
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of glucagon-like peptide-1 on major cardiovascular outcomes in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Ding S; Du YP; Lin N; Su YY; Yang F; Kong LC; Ge H; Pu J; He B
    Int J Cardiol; 2016 Nov; 222():957-962. PubMed ID: 27526367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of patients with type 2 diabetes mellitus: cardiovascular safety of incretin-based therapy supported by the ELIXA and TECOS trials].
    Avogaro A
    G Ital Cardiol (Rome); 2016 Apr; 17(4):248-52. PubMed ID: 27093207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Effects of Incretin-Based Therapies.
    White WB; Baker WL
    Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
    Jermendy G
    Orv Hetil; 2016 Apr; 157(16):603-10. PubMed ID: 27063427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Incretin-based therapies and cardiovascular outcome: analyses, pooled analyses and meta-analyses].
    Mannucci E
    G Ital Cardiol (Rome); 2012 Dec; 13(12 Suppl 1):4S-8S. PubMed ID: 23258123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and Renal Outcomes of Incretin-based Therapies: A Review of Recent Clinical Trials.
    Kyriakos G; Quiles-Sanchez LV; Garmpi A; Farmaki P; Kyre K; Gkogkos S; Savvanis S; Memi E
    Curr Cardiol Rev; 2020; 16(4):253-257. PubMed ID: 31161994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretins: cardiovascular safety and rationale for use.
    Kok A
    Cardiovasc J Afr; 2013 Mar; 24(2):46. PubMed ID: 23750348
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials.
    Wang T; Wang F; Zhou J; Tang H; Giovenale S
    Diabetes Metab Res Rev; 2016 Nov; 32(8):843-857. PubMed ID: 27037787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential cardiovascular effects of incretin-based therapies.
    Deacon CF; Marx N
    Expert Rev Cardiovasc Ther; 2012 Mar; 10(3):337-51. PubMed ID: 22390806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Yin and the Yang of CV risks in patients with diabetes.
    Dangi-Garimella S
    Am J Manag Care; 2014 May; 20(8 Spec No.):E6. PubMed ID: 25617925
    [No Abstract]   [Full Text] [Related]  

  • 14. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
    Green JB
    Postgrad Med; 2012 Jul; 124(4):54-61. PubMed ID: 22913894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of incretin-based therapies on cardiovascular disease.
    Rotz ME; Ganetsky VS; Sen S; Thomas TF
    Int J Clin Pract; 2015 May; 69(5):531-49. PubMed ID: 25363540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unraveling the association of heart failure from drug and disease: Insights from recent cardiovascular trials in type 2 diabetes mellitus.
    Peters MN; Pollock JS; Rajagopalan S
    J Diabetes Complications; 2016 Mar; 30(2):189-91. PubMed ID: 26632087
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.
    Kim JY; Yang S; Lee JI; Chang MJ
    PLoS One; 2016; 11(4):e0153502. PubMed ID: 27078018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-analysis of data from 58,160 patients in 13 randomized controlled trials.
    Fang HJ; Zhou YH; Tian YJ; Du HY; Sun YX; Zhong LY
    Int J Cardiol; 2016 Sep; 218():50-58. PubMed ID: 27236108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
    Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
    Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.